| Trial ID: | L1353 |
| Source ID: | NCT01475123
|
| Associated Drug: |
Nicorandil
|
| Title: |
Prospective Study of End Stage Renal Disease Patients With Coronary Artery Disease Treated by Oral Nicorandil
|
| Acronym: |
|
| Status: |
ACTIVE_NOT_RECRUITING
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Coronary Artery Disease|End Stage Renal Disease
|
| Interventions: |
DRUG: Nicorandil
|
| Outcome Measures: |
Primary: The primary endpoint is composite of :1) cardiovascular death 2)sudden cardiac death 3)nonfatal myocardial infarction 4)Hospitalization for recurrent symptomatic myocardial ischemia 5)stroke, 2 years | Secondary: Total mortality, 2 years|revascularization therapy, 2 years|hospitalization for heart failure, 2 years|hospitalization for peripheral artery disease, 2 years|newly onset of atrial fibrillation, 2 years
|
| Sponsor/Collaborators: |
Sponsor: Kumamoto University
|
| Gender: |
ALL
|
| Age: |
CHILD, ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
268
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION
|
| Start Date: |
2008-06
|
| Completion Date: |
2024-12
|
| Results First Posted: |
|
| Last Update Posted: |
2024-03-07
|
| Locations: |
Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, 860-8556, Japan
|
| URL: |
https://clinicaltrials.gov/show/NCT01475123
|
